Natamycin
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00826 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 43 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | vulvovaginal candidiasis | KG + DL |
| 2 | candidiasis | KG + DL |
| 3 | vulvitis | KG + DL |
| 4 | vulvovaginitis | KG + DL |
| 5 | trichomonal vulvovaginitis | KG + DL |
| 6 | postmenopausal atrophic vaginitis | KG + DL |
| 7 | ulceration of vulva | KG + DL |
| 8 | vulvar neoplasm | KG + DL |
| 9 | vaginitis (disease) | KG + DL |
| 10 | tinea nigra | KG + DL |
| 11 | oral candidiasis | KG + DL |
| 12 | vaginal discharge | KG + DL |
| 13 | commissural lip fistula | KG + DL |
| 14 | bacterial vaginosis | KG + DL |
| 15 | burning mouth syndrome | KG + DL |
| 16 | oral leukoedema | KG + DL |
| 17 | osteoradionecrosis of the mandible | KG + DL |
| 18 | leukoplakia of vagina | KG + DL |
| 19 | herpetic vulvovaginitis | KG + DL |
| 20 | dermatophytosis | KG + DL |
| 21 | anogenital human papillomavirus infection | KG + DL |
| 22 | fungal infectious disease | KG + DL |
| 23 | breast fibrocystic disease | KG + DL |
| 24 | apocrine adenosis of breast | KG + DL |
| 25 | blunt duct adenosis of breast | KG + DL |
| 26 | oral hairy leukoplakia | KG + DL |
| 27 | salivary gland disease | KG + DL |
| 28 | tongue disease | KG + DL |
| 29 | benign mammary dysplasia | KG + DL |
| 30 | immunodeficiency due to a genetic complement cascade protein anomaly | KG + DL |
| 31 | T-cell immunodeficiency with epidermodysplasia verruciformis | KG + DL |
| 32 | familial isolated congenital asplenia | KG + DL |
| 33 | breast abscess | KG + DL |
| 34 | fat necrosis of breast | KG + DL |
| 35 | epidermodysplasia verruciformis | KG + DL |
| 36 | lactation disease | KG + DL |
| 37 | common wart | KG + DL |
| 38 | neoplasm of jaw | KG + DL |
| 39 | breast adenosis | KG + DL |
| 40 | autosomal recessive primary immunodeficiency with defective spontaneous natural killer cell cytotoxicity | KG + DL |
| 41 | primary immunodeficiency with post-measles-mumps-rubella vaccine viral infection | KG + DL |
| 42 | piedra | KG + DL |
| 43 | varicella zoster infection | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.